Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study to Determine the MTD and to Evaluate Pharmacokinetic, Safety/Tolerability, and Efficacy Profiles of IOP Injection for MRI Contrast Agent in Healthy Subjects

NCT02744248 is registered in ClinicalTrials.gov with MegaPro Biomedical Co. Ltd. as lead sponsor.

NCT NCT02744248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02744248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study to Determine the MTD and to Evaluate Pharmacokinetic, Safety/Tolerability, and Efficacy Profiles of IOP Injection for MRI Contrast Agent in Healthy Subjects
Lead sponsor
MegaPro Biomedical Co. Ltd.
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2016
Completion date
December 31, 2017
Enrollment
24 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

magnetic resonance imaging